Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer

• Published in: PloS one 2020-12, Vol.15 (12), p.e0243379-e0243379
• Main Authors: Azuma, Takeshi, Sato, Yujiro, Ohno, Tatsukuni, Azuma, Miyuki, Kume, Haruki
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Aged, 80 and over; B7 antigen; B7 Antigens - blood; B7 Antigens - immunology; Biology and Life Sciences; Biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - immunology; Bladder; Bladder cancer; Cancer; Cytokines; Development and progression; Enzyme-linked immunosorbent assay; Evaluation; Female; Gastric cancer; Hazard assessment; Health care facilities; Humans; Identification and classification; Immune serums; Immunology; Invasiveness; Kidney cancer; Ligands (Biochemistry); Liver cancer; Lymphocytes; Lymphocytes T; Male; Medical prognosis; Medicine and Health Sciences; Middle Aged; Multivariate analysis; Muscles; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - immunology; Neoplasm Recurrence, Local - pathology; Patients; Prognosis; Prostate cancer; Regression analysis; Regression models; Risk groups; Survival; T-Lymphocytes - immunology; T-Lymphocytes - pathology; Tumor markers; Urinary Bladder Neoplasms - blood; Urinary Bladder Neoplasms - immunology; Urinary Bladder Neoplasms - pathology; Urology
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0243379

B7-H3 is a member of the B7 family of immune-regulatory ligands and is a costimulatory molecule promoting the T cell response in vitro. We herein investigated the clinical utility of serum soluble B7-H3 (sB7-H3) in patients with non-muscle invasive bladder cancer (NMIBC). We analyzed 555 patients in whom NMIBC was diagnosed at Tokyo Metropolitan Tama Medical Center between 2008 and 2013. We measured the serum sB7-H3 (sB7-H3) level using the enzyme-linked immunosorbent assay (ELISA) and evaluated the utility of sB7-H3 as a prognostic biomarker for NMIBC. We used the Cox proportional hazards regression model to assess recurrence-free survival (RFS) and progression-free survival (PFS) with the sB7-H3 level. We detected high levels of sB7-H3 in the sera of 47% of patients with NMIBC versus only 8% in healthy donors. The increase of sB7-H3 was significantly associated with poor RFS and PFS. Multivariate analysis showed that elevated sB7-H3 was an independent prognostic factor of RFS and PFS. According to the European Organization for Research and Treatment of Cancer (EORTC), in intermediate-low and intermediate-high risk groups, the presence of sB7-H3 significantly determined the rate of recurrence and progression. Our data suggested that evaluating serum sB7-H3 expression is a useful tool for predicting the prognosis of patients with NMIBC.